Dr. Antin-Ozerkis received her Bachelor’s degree from Princeton University. She went on to complete her medical degree, residency, and fellowship in Pulmonary and Critical Care Medicine at the University of Pennsylvania, where she pursued advanced fellowship training in the evaluation and management of advanced lung disease and lung transplant patients. She came to Yale in 2006. Dr. Antin-Ozerkis is Medical Director of the Yale Interstitial Lung Disease Center of Excellence. Her specific area of clinical expertise is the diagnosis and treatment of interstitial lung diseases (ILD), with a focus on idiopathic pulmonary fibrosis (IPF) and connective tissue disease-associated interstitial lung disease (CTD-ILD). She leads a multidisciplinary group which meets weekly to review patient cases, offering consensus opinions on diagnosis and management. As part of a comprehensive approach to patient care, Yale ILD offers clinical drug trials for patients with IPF and other forms of pulmonary fibrosis. Dr. Antin-Ozerkis is the primary investigator at Yale for these studies. She participates in the Center’s translational research program which is aimed at understanding the mechanisms of pulmonary fibrosis development and progression.